

Bharat Parenterals Limited
Registered Office : Vill. Haripura, Ta. Savli, Dist. Vadodara - 391520, (Guj.) India
Corporate Office : Shree Avenue, 1st Floor, Above Bank of Baroda, Nr. Amit Nagar Circle, VIP
CIN : U24231SJ1992PLC018237. Website : www.bplindia.in

Statement of standalone Unaudited Financial Results for the Quarter ended Dec 31, 2016

(Rs.)

Particulars	Quarter ended			Year ended
	31.12.2016	30.09.2016	31.12.2015	31.03.2016
	Unaudited	Unaudited	Unaudited	Audited
Income from Operations				
Net Sales / Income from Operations	270,389,723	267,411,746	246,168,830	1,197,367,568
Other Operating Income	18,738,196	18,531,820	9,688,767	47,126,257
Total Income from Operations	289,127,919	285,943,566	255,857,597	1,244,493,825
Expenses				
Cost of materials consumed	195,698,305	193,542,953	172,455,755	838,826,457
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3,002,556)	(2,969,487)	(1,796,141)	(8,736,447)
Employee benefits expense	26,865,244	26,569,360	20,253,898	98,515,155
Depreciation and amortisation expense	14,076,813	13,921,776	8,642,837	42,038,842
Other expenses	33,829,828	33,457,238	34,032,363	165,533,740
Total Expenses	267,457,635	264,521,841	233,588,711	1,136,177,747
Profit / Loss from Operations before Other Income, Finance Costs and Exceptional Item	21,670,284	21,421,725	22,268,886	108,316,077
Other income extraordinary income	-	-	-	-
Profit / Loss from ordinary activities before Finance Costs and Exceptional Item	21,660,284	21,421,725	22,268,886	108,316,077
Finance costs	2,200,686	2,176,448	3,055,196	14,860,504
Profit / Loss from ordinary activities after Finance Costs but before Exceptional Item	19,459,598	19,245,277	19,213,690	93,455,574
Exceptional item	-	-	-	-
Profit / Loss from ordinary activities before Tax	19,459,598	19,245,277	19,213,690	93,455,574
Tax expense and Deferred Tax	1,422,692	1,407,023	5,946,481	28,923,743
Net Profit / Loss for the quarter	18,036,906	17,838,254	13,267,209	64,531,831
Other Comprehensive Income (OCI) (net of tax)	-	-	-	-
Total Comprehensive Income for the quarter	18,036,906	17,838,254	13,267,209	64,531,831
Paid-up Equity Share Capital - Face Value 10 each (Rs)	5,729,666	5,729,666	5,729,666	5,729,666
Earnings Per Share of 10 each (Rs.)				
(Basic)	3.15	3.11	2.32	11.26
(Diluted)	3.15	3.11	2.32	11.26

Notes :

- The Company has only one reportable segment namely 'Pharmaceuticals'.
- Previous Quarter/Year figures have been regrouped wherever necessary to make it easy for comparing with the figures of current Quarter/Year.

For Alkesh J. Shah & Co.
Chartered Accountants

Place : VADODARA
Date : 25 /01 /2017



Proprietor

For and on behalf of the Board

(Signature)

Bharat R Desai
Managing Director



Alkesh J. Shah & Co.
Chartered Accountants
203, Opal Square, B/h. Express Hotel,
Alkapuri, Vadodara. ☎ : 0265-231 3074
Email : alkeshjshah@yahoo.co.in



Place: Vadodara
Date: 25/01/2017

ALKESH J. SHAH & CO.

Chartered Accountants
203, Opal Square,
Behind Hotel Express,
Alkapuri,
Vadodara
(O) 0265 231 3074

Email – alkeshjshah@yahoo.co.in

The Limited Review Report for companies (other than banks)

Review Report to Board of Directors, Bharat Parenterals Limited


We have reviewed the accompanying statement of unaudited financial results of Bharat Parenterals Limited having its registered office at Vill. Haripura, Tal. Savli, Dist. Vadodara-391520, for the period ended 31/12/2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For Alkesh J. Shah & Co.
Chartered Accountants


Alkesh J. Shah
Proprietor

(Membership Number)-038932

Place: Vadodara
Date: 25/01/2017

Bharat Parenterals Limited
Registered Office : VIII, Haripura, Ta. Savli, Dist. Vadodara - 391520. (Guj.) India
Corporate Office : Shree Avenue, 1st Floor, Above Bank of Baroda, Nr. Amit Nagar Circle, VIP
CIN : U24231GJ1992PLC018237, Website : www.bplindia.in

Statement of Consolidated Unaudited Financial Results for the Quarter and Year ended Dec 31, 2016

(Rs.)

Particulars	Quarter ended			Year ended
	31.12.2016	30.09.2016	31.12.2015	31.03.2016
	Unaudited	Unaudited	Unaudited	Audited
Income from Operations				
Net Sales / Income from Operations	271,067,492	267,411,746	246,168,830	1,197,367,568
Other Operating Income	18,738,196	18,531,820	9,688,767	47,126,257
Total Income from Operations	289,805,688	285,943,566	255,857,597	1,244,493,825
Expenses				
Cost of materials consumed	195,698,305	193,542,953	172,455,755	838,826,457
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3,002,556)	(2,969,487)	(1,796,141)	(8,736,447)
Employee benefits expense	28,145,335	26,569,360	20,253,898	98,515,155
Depreciation and amortisation expense	14,076,813	13,921,776	8,642,837	42,038,842
Other expenses	35,123,089	33,457,238	34,032,363	165,533,740
Total Expenses	270,040,987	264,521,841	233,588,711	1,136,177,747
Profit / Loss from Operations before Other Income, Finance Costs and Exceptional Item	19,764,701	21,421,725	22,268,886	108,316,077
Other income extraordinary income	-	-	-	-
Profit / Loss from ordinary activities before Finance Costs and Exceptional Item	19,764,701	21,421,725	22,268,886	108,316,077
Finance costs	2,207,874	2,176,448	3,055,196	14,860,504
Profit / Loss from ordinary activities after Finance Costs but before Exceptional Item	17,556,827	19,245,277	19,213,690	93,455,574
Exceptional item	-	-	-	-
Profit / Loss from ordinary activities before Tax	17,556,827	19,245,277	19,213,690	93,455,574
Tax expense and Deferred Tax	1,422,692	1,407,023	5,946,481	28,923,743
Net Profit / Loss for the quarter	16,134,135	17,838,254	13,267,209	64,531,831
Other Comprehensive Income (OCI) (net of tax)	-	-	-	-
Total Comprehensive Income for the quarter	16,134,135	17,838,254	13,267,209	64,531,831
Paid-up Equity Share Capital - Face Value 10 each (Rs.)	5,729,666	5,729,666	5,729,666	5,729,666
Earnings Per Share of 10 each (Rs.)				
(Basic)	2.82	3.11	2.32	11.26
(Diluted)	2.82	3.11	2.32	11.26

Notes :

- The Company has only one reportable segment namely 'Pharmaceuticals'.
- Previous Quarter/Year figures have been regrouped wherever necessary to make it easy for comparing with the figures of current Quarter/Year.

For Alkesh J. Shah & Co.
Chartered Accountants

Place : VADODARA

Date : 25/01/17




Proprietor

For and on behalf of the Board

(Signature)

Bharat R Desai
Managing Director





ALKESH J. SHAH & CO.


Chartered Accountants
203, Opal Square,
Behind Hotel Express,
Alkapuri,
Vadodara – 390007
(M) 98250 28121
Email – alkeshjshah@yahoo.co.in

To,
The Board of Directors,
Bharat Parenterals Limited
Vadodara

Limited Review Report on Consolidated Quarterly Financial Results of Bharat Parenterals Limited pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

We have reviewed the accompanying statement of consolidated unaudited financial results ("the Statement") of Bharat Parenterals Limited ("the Company") wherein are included unaudited financial results of its subsidiary for the quarter ended on 31st December, 2016. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. The statement has been prepared by the company pursuant to the regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/FAC/62/2016 dated 5th July, 2016 which has been initialed by us for the identification purpose. Management is responsible for the preparation and fair presentation of this consolidated interim financial information. Our responsibility is to express a conclusion on this consolidated interim financial information based on our review.

We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurances as to whether the statement of financial results is free of material misstatement. A review is limited primarily





ALKESH J. SHAH & CO.

Chartered Accountants
203, Opal Square,
Behind Hotel Express,
Alkapuri,
Vadodara – 390007
(M) 98250 28121
Email – alkeshjshah@yahoo.co.in


to inquiries of Company personnel and analytical procedures applied to financial data and thus, provide less assurance than an audit. We have not performed an audit and thus, we do not express an audit opinion.

We report that the unaudited consolidated financial results have been prepared by the company's management in accordance with and on the basis of the separate unaudited financial results of its subsidiary. These unaudited financial results have not been verified by us. These are as prepared by the Company's management and included in the consolidated results as submitted to us. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/FAC/62/2016 dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatements.

Place: Vadodara
Date: 25/01/17



For Alkesh J. Shah & Co.


Alkesh J. Shah
Proprietor
Membership No.: 038932

